[Skip to Content]

Upstate Active Clinical Trials

Study Title:

INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia

What is the purpose of the study?

This research study will find out if the study drug, ruxolitinib, in combination with standard HR B-ALL treatment is safe and effective in children, adolescents, and young adults with HR B-ALL.

Upstate Institutional Review Board (IRB) Number:

950255

Study/Protocol ID:

COG AALL1521

Study Phase:

Phase II

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who can I contact for more information?

Name: Beatriz Kovar
Phone: 315-464-7232
Email: kovarb@upstate.edu

Return to Previous Page || Search Again

Top